CN108179114B - 产抗厌氧菌化合物的菌株和发酵方法、抗厌氧菌化合物提取及制备方法和使用方法 - Google Patents

产抗厌氧菌化合物的菌株和发酵方法、抗厌氧菌化合物提取及制备方法和使用方法 Download PDF

Info

Publication number
CN108179114B
CN108179114B CN201711202062.0A CN201711202062A CN108179114B CN 108179114 B CN108179114 B CN 108179114B CN 201711202062 A CN201711202062 A CN 201711202062A CN 108179114 B CN108179114 B CN 108179114B
Authority
CN
China
Prior art keywords
ustusol
strain
anaerobic
anaerobic bacteria
ustisol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201711202062.0A
Other languages
English (en)
Other versions
CN108179114A (zh
Inventor
霍光明
张李阳
刘维周
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Xiaozhuang University
Original Assignee
Nanjing Xiaozhuang University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Xiaozhuang University filed Critical Nanjing Xiaozhuang University
Priority to CN201711202062.0A priority Critical patent/CN108179114B/zh
Publication of CN108179114A publication Critical patent/CN108179114A/zh
Application granted granted Critical
Publication of CN108179114B publication Critical patent/CN108179114B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • C12N1/145Fungal isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/645Fungi ; Processes using fungi
    • C12R2001/66Aspergillus
    • C12R2001/70Aspergillus ustus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/74Separation; Purification; Use of additives, e.g. for stabilisation
    • C07C29/76Separation; Purification; Use of additives, e.g. for stabilisation by physical treatment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/74Separation; Purification; Use of additives, e.g. for stabilisation
    • C07C29/76Separation; Purification; Use of additives, e.g. for stabilisation by physical treatment
    • C07C29/86Separation; Purification; Use of additives, e.g. for stabilisation by physical treatment by liquid-liquid treatment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/22Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
    • C07C35/23Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings
    • C07C35/36Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings the condensed ring system being a (4.4.0) system, e.g. naphols
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78Separation; Purification; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78Separation; Purification; Stabilisation; Use of additives
    • C07C45/79Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78Separation; Purification; Stabilisation; Use of additives
    • C07C45/80Separation; Purification; Stabilisation; Use of additives by liquid-liquid treatment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00Compounds having —CHO groups
    • C07C47/38Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
    • C07C47/46Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00Preparation of oxygen-containing organic compounds
    • C12P7/02Preparation of oxygen-containing organic compounds containing a hydroxy group
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00Preparation of oxygen-containing organic compounds
    • C12P7/24Preparation of oxygen-containing organic compounds containing a carbonyl group
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18Testing for antimicrobial activity of a material
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本发明涉及微生物学、发酵工程、微生物制药等领域,公开了产抗厌氧菌化合物的菌株和发酵方法、抗厌氧菌化合物提取及制备方法和使用方法,菌株保藏编号为CCTCC NO:M 2017715,分类命名为Aspergillus ustus A2;该该菌株的次级代谢产物包括选育的真菌代谢产物ustusol H1,ustusolH2,ustusolH3,ustusol H4和TMC‑120 C。本发明提供了鉴定的菌株培养物的rDNA序列。本发明还提供了该菌株的生产培养基和培养条件,以及该菌株使用方法。本发明制备的ustusol H1,ustusolH2,ustusolH3,ustusol H4和TMC‑120 C具有抗双岐杆菌、乳酸杆菌、韦荣球菌、厌氧链球菌、伊氏放线菌、厌氧链球菌、普通拟杆菌、消化链球菌等厌氧菌的功能,在治疗口腔疾病等厌氧菌引起病症中得到应用,亦可在食品或发酵领域用于抗厌氧菌。

Description

产抗厌氧菌化合物的菌株和发酵方法、抗厌氧菌化合物提取 及制备方法和使用方法
技术领域
本发明涉及微生物学、发酵工程、微生物制药等领域,具体涉及产抗厌氧菌 化合物的菌株和发酵方法、抗厌氧菌化合物提取及制备方法和使用方法。本发明 选育的真菌代谢产物ustusol H1,ustusolH2,ustusolH3,ustusol H4和TMC-120 C具有抗双岐杆菌、乳酸杆菌、韦荣球菌、厌氧链球菌、伊氏放线菌、厌氧链 球菌、普通拟杆菌、消化链球菌等厌氧菌的功能,在治疗口腔疾病等厌氧菌引起 病症中得到应用,亦可在食品或发酵领域用于抗厌氧菌。
背景技术
厌氧菌是指一类能在低氧分压的情况下,而不能在空气或浓度下固体培养基 表面生长的细菌。厌氧菌广泛存在人类皮肤和腔道的深部黏膜表面,大多数对人 体无害,但在组织缺血、坏死或者需氧菌感染情况下会诱发感染,多见于腹腔内 感染、牙周炎及妇科炎症、外伤及上呼吸道感染等一系列疾病中,参入这些感染 的微生物常见抗双岐杆菌、乳酸杆菌、韦荣球菌、厌氧链球菌、伊氏放线菌、厌 氧链球菌、普通拟杆菌、消化链球菌等。随着抗生素的使用,厌氧菌的耐药性也 呈快速趋势。因此寻找和开发具有广谱抗厌氧菌的化合物已成当务之急。
随着人类生活节奏加快和食品工业发展,真空包装食品和罐头等快捷食品已 成为食品消费重要组成部分。厌氧菌的污染已成为影响上述食品卫生质量的重要 原因,因此,开发安全的抗厌氧菌的食品添加剂也是食品工业所急需。
发明内容
针对上述问题,本发明的目的在于,提出一种产抗厌氧菌化合物的菌株和发 酵方法、抗厌氧菌化合物提取及制备方法和使用方法,该菌株属植物内生真菌, 通过固体发酵生产方法生产抗厌氧菌浸膏,通过分离制备技术得到ustusol H1, ustusolH2,ustusolH3,ustusol H4和TMC-120C 5个化合物具有抗厌氧菌功能。
一株产抗厌氧菌化合物的菌株,其为曲霉属,由中国典型培养物保藏中心 CCTCC保藏,保藏编号为CCTCC NO:M 2017715,分类命名为Aspergillus ustus A2。
该菌株从榆树的叶分离培养而得,该菌株生产的抗厌氧菌化合物包括4个结 构新型的补身烷类倍半萜化合物ustusol H1(即焦曲霉素H1,全称为 (1R,4S,8aS)-1,4-二羟--2,5,5,8a-四甲基-1,4,4a,5,6,7,8,8a-八甲焦磷酸酰胺-1-甲醛), ustusol H2(即焦曲霉素H2,全称为4-羟甲基-3,4a,8,8-四甲基-1,2,4a,5,6,7,8,8a- 八甲焦磷酸酰胺-1,2-二醇),ustusol H3(即焦曲霉素H3,全称为(1R,8aS)-1-羟 甲基-2,5,5,8a-四甲基-1,2,4a,5,6,7,8,8a-八甲焦磷酸酰胺-1,2-二醇),ustusol H4(即 焦曲霉素H4,全称为1R,8aS)-1-羟甲基-5,5,8a-三甲基-2-亚甲基-1,2,4a,5,6,7,8,8a- 八甲焦磷酸酰胺-1-醇)和已知化合物TMC-120C(2-(7-甲基-2,3-二氢呋喃[3,2-h] 异喹啉-2-yl)丙醇-2-醇)。
真菌CCTCC NO:M 2017715的菌落特征:菌落在麦芽固体培养基28℃培养 7天直径30-35mm,菌落呈灰褐色,边缘白色,质地棉絮状,无渗出液;菌落反 面不均匀的黄褐色。气生菌丝生长良好,分生孢子着生于气生菌丝。顶囊球形或 半球形,6-13um(图1)。
根据微生物形态结合ITS序列,该真菌定名为Aspergillus ustus A2。
本发明的另一个目的是提供该菌中在制备ustusol H1,ustusolH2,ustusolH3,ustusol H4和TMC-120C的5个抗厌氧菌化合物的应用。
真菌CCTCC NO:M 2017715的菌株可用于发酵制备ustusol H1,ustusolH2,ustusolH3,ustusol H4和TMC-120C等5个抗厌氧菌化合物。该制备方法包括 下列步骤:
(a)发酵菌株:采用真菌CCTCC NO:M 2017715的菌株;
(b)菌株培养:真菌CCTCC NO:M 2017715的菌株在25℃,麦芽固体培 养基活化培养7d后,取0.5cm2菌块接种到400mL麦芽液体培养基, 在24℃恒温振荡箱中培养5d,得到该真菌液体种子液;将上述真菌 液体种子液按8%接种量,接种到50g固体生产培养基,放置22℃ 恒温培养箱中培养25d,结束发酵,得到含有抗厌氧菌化合物的发酵 产物。
(c)发酵产物的提取,色谱层析和HPLC制备
其中步骤(b)所述的所述麦芽固体培养基的组成为:生麦芽20g、蛋白胨 2g、羧甲基纤维素钠1g,K2HPO4 1g、KCl 0.5g、MgSO4 0.5g、FeSO4 0.01g、 酵母膏1g,琼脂粉20g,加水溶解至1000ml、分装、灭菌后备用。或者不加琼 脂,其余步骤与麦芽固体培养基的制备相同,形成麦芽液体培养基。固体生产培 养基的制备步骤为:生麦芽20g、大米20g、麸皮10g,玉米芯10g,维生素C 0.5g,混合均匀后,加入72毫升水浸泡4h,灭菌后为固体生产培养基。
其中步骤(c)中发酵产物提取按照1:8(发酵产物质量:甲醇体积比)加 入甲醇,25℃超声震荡30min,抽滤得到提取液。上述提取液中加入石油醚(1: 1,即石油醚与提取液的体积比)进行萃取,取甲醇部分(甲醇位于石油醚上方, 且甲醇中混有发酵产物)在40℃下抽真空旋转蒸发得到含抗厌氧菌化合物的浸 膏。
其中步骤(c)中发酵产物色谱层析按照将上述浸膏通过流动相为甲醇:水 (含0.1%HF),在反向色谱柱上进行梯度洗脱。收集甲醇:水(含0.1%HF, 0.1%为体积浓度)60-65%(百分比为甲醇的体积比,以下同)段,旋转蒸发仪 蒸干,通过HPLC制备得到ustusol H1,ustusolH2,ustusolH3和ustusol H4。 收集甲醇:水(含0.1%HF)70%(甲醇体积比)段,旋转蒸发仪蒸干,通过HPLC 制备得到TMC-120C。
其中步骤(c)中所述ustusol H1,ustusolH2,ustusolH3和ustusol H4的HPLC 制备条件是:色谱柱Allsphere ODS-2.5μm(250×4.6mm),柱温30℃,流动相 甲醇:水60%,出峰时间分别为16.2min,18.2min,21.05min和25.5min。2.5μm 为填充材料粒度,250×4.6mm为柱长250mm*柱之内径4.6mm。
其中步骤(c)中所述TMC-120C的HPLC制备条件是:色谱柱Allsphere ODS-2.5μm(250×4.6mm),柱温30℃,流动相甲醇:水65%,出峰时间为 7.5min。
真菌CCTCC NO:M 2017715的菌株所产抗厌氧菌化合物的使用方法,其特征 是,所述方法包括以下步骤:
(a)抗厌氧菌化合物准备
将化合物ustusol H1,ustusolH2,ustusolH3、ustusolH4和TMC-120C用 无菌水分别制成各自浓度为128μg/mL的母液;即一种母液中单独加入一种化合 物;用MH(细菌)培养基肉汤稀释到试验所需浓度。
(b)测试菌种制备
将双岐杆菌、乳酸杆菌、韦荣球菌、厌氧链球菌、伊氏放线菌、厌氧链球菌、 普通拟杆菌、消化链球菌分别从平板上挑菌落至MH肉汤培养基培养(一般2-6hr) 至混浊度达到0.5Mc加样接种。37℃培养16-24h,MTT法测定抗菌活性。
其中一类抗厌氧菌化合物的应用方法,上述步骤(a)和(b)中MH肉汤培 养基的组成:牛肉浸膏2g,可溶性淀粉1.5g,酸水解酪蛋白17.5g,pH值7.4±0.2, 加水溶解至1000ml、分装、灭菌后备用。
相对于现有技术,本发明的有益效果是:
筛选得到的真菌Aspergillus ustus A2,能够发酵得到ustusol H1,ustusol H2,ustusol H3,ustusol H4和TMC-120C这五种抗厌氧菌化合物,能对多种厌氧菌 进行抑制、消除,具有广谱性,且抑菌效果好;本发明制备的发酵产物ustusol H1, ustusolH2,ustusolH3,ustusol H4和TMC-120C具有抗双岐杆菌、乳酸杆菌、韦 荣球菌、厌氧链球菌、伊氏放线菌、厌氧链球菌、普通拟杆菌、消化链球菌等厌 氧菌的功能,在治疗口腔疾病等厌氧菌引起病症中得到应用,亦可在食品或发酵 领域用于抗厌氧菌。
ustusol H1,ustusol H2,ustusol H3,ustusol H4和TMC-120C这五种化合物 均可通过HPLC实现分离,操作方便。
附图说明
图1为CCTCC NO:M 2017715的菌株形态图;
图2为ustusol H1 1H NMR图;
图3为ustusol H1 13C NMR图
图4为ustusol H2 1H NMR图;
图5为ustusol H2 13C NMR图;
图6为ustusol H3 1H NMR图;
图7为ustusol H3 13C NMR图;
图8为ustusol H4 1H NMR图;
图9为ustusol H4 13C NMR图;
图10为TMC-120C H1 1H NMR图;
图11Aspergillus ustus A2产抗厌氧菌化合物结构式ustusol H1,ustusolH2,ustusolH3、ustusolH4和TMC-120C;
表1为ustusol H1,ustusolH2,ustusolH3、ustusolH4和TMC-120C抗厌 氧菌结果。
序列表为CCTCC NO:M 2017715菌株的ITS rDNA序列鉴定结果。
生物材料样品保藏:
Aspergillus ustus A2已保藏于中国武汉大学“中国典型培养物保藏中心”,即CCTCC,保藏地址:湖北省武汉市武昌珞珈山,保藏编号为 CCTCC NO:M 2017715,保藏日期为2017年11月22日。
具体实施方式
为进一步揭示本发明的技术方案,下面结合附图详细说明本发明的实施方式:
本发明中所用培养基为:
麦芽固体培养基:生麦芽20g、蛋白胨2g、羧甲基纤维素钠1g,K2HPO4 1g、KCl 0.5g、MgSO4 0.5g、FeSO4 0.01g、酵母膏1g,琼脂粉20g,加水溶 解至1000ml、分装、灭菌后备用。
麦芽液体培养基:不加琼脂,其余步骤与麦芽固体培养基的制备相同,形成 麦芽液体培养基。
固体生产培养基:生麦芽20g、大米20g、麸皮10g,玉米芯10g,维生素 C 0.5g,混合均匀后,加入72毫升水浸泡4h,灭菌后为固体生产培养基。
实施例1
Aspergillus ustus A2的发酵过程:
(a)菌株培养:真菌CCTCC NO:M 2017715的菌株在25℃,麦芽固体培 养基活化培养7d后,取0.5cm2菌块接种到400mL麦芽液体培养基, 在24℃恒温振荡箱中培养5d,得到该真菌液体种子液;将上述真菌 液体种子液按8%接种量,接种到50g固体生产培养基,放置22℃ 恒温培养箱中培养25d,结束发酵,得到含有抗厌氧菌化合物的发酵 产物。
实施例2
发酵产物的提取,色谱层析和HPLC制备过程:
发酵产物提取按照1:8(质量:体积比)加入甲醇,25℃超声震荡30min,抽 滤得到提取液。上述提取液中加入石油醚(1:1)进行萃取,取甲醇部分在40℃ 下抽真空旋转蒸发得到含抗厌氧菌化合物的浸膏。上述浸膏通过流动相为甲醇: 水(含0.1%HF),在反向色谱柱上进行梯度洗脱。收集甲醇:水(含0.1%HF) 60-65%段,旋转蒸发仪蒸干,通过HPLC制备得到ustusol H1,ustusolH2, ustusolH3和ustusol H4。收集甲醇:水含0.1%HF)70%段,旋转蒸发仪蒸干, 通过HPLC制备得到TMC-120C。H4HPLC制备条件是:色谱柱AllsphereODS-2.5μm(250×4.6mm),柱温30℃,流动相甲醇:水60%,出峰时间分别 为16.2min,18.2min,21.05min和25.5min,分别制备得:ustusol H1,ustusolH2, ustusolH3和ustusolH4。HPLC制备条件是:色谱柱Allsphere ODS-2.5μm(250× 4.6mm),柱温30℃,流动相甲醇:水65%,出峰时间为7.5min,制备的化合 物TMC-120C。化合物得率ustusol H1 12mg/Kg,ustusol H2 6mg/Kg,ustusolH3 4.2mg/Kg和ustusol H4 8.6mg/Kg,TMC-120C 32mg/Kg。
根据图2-11,ustusol H1,ustusolH2,ustusolH3、ustusolH4和TMC-120C 的结构已确认,其中ustusol H1,ustusolH2,ustusolH3、ustusolH4为结构新颖 化合物,TMC-120C为首次在Aspergillus ustus A2中发现。
ustusol H1
MP:174-175℃.
[α]D:+10.8(c 1.00,MeOH).
IR(KBr):3338,2944,2832,2522,1450,1030,672cm-1.
1H NMR(500MHz,Acetone-d6):1.12(3H,s,13-Me),1.18(3H,s,15-Me),1.29(3H,s,14-Me),1.28(1H,m,H-3), 1.37(1H,m,H-3),1.46(1H,m,H-1),1.50(1H,m,H-1),1.54(1H,m,H-2),1.60(3H,d,J=1.7Hz,H-12),1.64(1H, d,J=2.4Hz,H-5),1.72(1H,m,H-2),4.28(1H,dt,J=10.2,2.4Hz,H-6),5.83(1H,dq,J=10.2Hz,1.7Hz,H-7), 9.79(H,s,11-CHO)
13C NMR(500MHz,Acetone-d6):18.1(CH2),18.5(CH3),18.9(CH3),23(CH3),33.3(C),33.9(CH2),36.3(CH3), 43(CH2),43.5(C),49.8(CH),70(CH-OH),82.6(C-OH),130.9(C),133.8(CH),205.9(C=O).
HRMS-FAB:m/z[M+Na+]calcd for C15H24O3:275.16177;found:275.16185.
ustusol H2
MP:163-165℃.
[α]D:+18.3(c 1.00,MeOH).
IR(KBr):3334,2945,2833,2522,2045,1669,1498,1116,1032,666cm-1.
1H NMR(500MHz,Acetone-d6):1.79(1H,d,J=11.5Hz,H-1),1.50(1H,m,H-1),1.72(1H,m,H-2),1.54(1H,m, H-2),1.74(1H,m,H-3),1.38(1H,m,H-3),4.2(1H,s,H-6),3.6(1H,s,H-7),4.28(1H,d,J=12Hz,H-11),4.18(1H, d,J=12Hz,H-11),1.81(1H,s,H-12),0.97(1H,s,H-13),1.23(1H,s,H-14),1.32(1H,s,H-15).
13C NMR(500MHz,Acetone-d6):39.3(CH2),19.9(CH2),44.0(CH2),34.2(C),49.5(CH),72.0(CH),76.7(CH), 130.6(C),144.8(C),57.8(CH2),17.8(CH3),21.8(CH3),24.2(CH3),33.9(CH3).
HRMS-FAB:m/z[M+Na+]calcd for C15H26O3:277.17742;found:277.1754.
ustusol H3
MP:184-186℃.
[α]D:+174.8(c 1.00,MeOH).
IR(KBr):3339,2945,2833,2522,2045,1450,1116,1035,665cm-1.
1H NMR(500MHz,Acetone-d6):0.9(3H,s,13-Me),0.93(3H,s,14-Me),1.08(3H,s,14-Me),1.16(1H,td,J= 13.1Hz,3.1Hz,H-3),1.29(3H,s,12-Me),1.39(1H,d,J=3.1Hz,H-3),1.45(1H,m,H-2),1.6(1H,td,J=13.2 Hz,2.2Hz,H-1),1.67(1H,dddd,J=12.9Hz,10.9Hz,3.2Hz H-2),2.48(1H,brs,H-5),3.78(1H,d,J=11.4Hz, H-11),4.0(1H,d,J=11.4Hz,H-11),5.51(1H,dd,J=10.3Hz,2.9Hz,H-7),5.65(1H,d,J=10.3Hz,H-6).
13C NMR(500MHz,Acetone-d6):17.2(CH3),19(CH2),22.7(CH3),26.9(CH3),32.3(CH2),32.9(C),33.2(C), 33.5(CH3),42(CH2),45.8(CH),61.1(CH2),73.9(C),76.9(C),127.3(CH),135.0(CH).
HRMS-FAB:m/z[M+Na+]calcd for C15H24O3:275.16177;found:275.17553.
ustusol H4
MP:141-175℃..
[α]D:+75.3(c 1.00,MeOH).
IR(KBr):3332,2944,2832,2522,2045,1450,1116,1034,659cm-1.
1H NMR(500MHz,Acetone-d6):1.21(1H,td,J=12.9Hz,3.8Hz,H-1),1.41(1H,m,H-1),1.57(1H,m,H-2), 1.65(1H,qt,J=13.1Hz,3.3Hz,H-2),1.44(1H,td,J=10.9Hz,3.5Hz,H-3),1.67(1H,ddd,J=10.9Hz,3.4Hz, 3.3Hz,H-3),2.59(1H,s,H-5),6.17(1H,dd,J=0.65Hz,10.3Hz,H-6),6.05(1H,dd,J=3.3Hz,10.3Hz,H-7), 3.79(1H,d,J=10.8Hz,H-11),3.89(1H,d,J=10.8Hz,H-11),5.48(1H,d,J=1.2Hz,H-12),4.92(1H,d,J= 0.65Hz,H-12),0.8(3H,s,13-Me),0.91(3H,s,14-Me),0.98(3H,s,15-Me).
13C NMR(500MHz,Acetone-d6):16.6(CH3),19.5(CH2),22.8(CH3),31.6(CH2),33.4(C),33.5(CH3),41.7(CH2), 42.1(C),47.8(CH),62.3(CH2),75.9(C),113.9(CH2),130.0(CH),130.3(CH),148.0(C).
HRMS-FAB:m/z[M+Na+]calcd for C15H24O2:259.16685;found:259.1854.
实施例3
所产抗厌氧菌化合物的应用方法:
(a)抗厌氧菌化合物准备
将化合物ustusol H1,ustusolH2,ustusolH3、ustusolH4和TMC-120C用 无菌水分别制成浓度128μg/mL母液。用MH(细菌)培养基肉汤稀释到试验所需 浓度。
(b)测试菌种制备
将双岐杆菌、乳酸杆菌、韦荣球菌、厌氧链球菌、伊氏放线菌、厌氧链球菌、 普通拟杆菌、消化链球菌分别从平板上挑菌落至MH肉汤培养基培养(一般2-6hr) 至混浊度达到0.5Mc加样接种。37℃培养16-24h,MTT法测定抗菌活性。
上述步骤(a)和(b)中MH肉汤培养基的组成:牛肉浸膏2g,可溶性淀 粉1.5g,酸水解酪蛋白17.5g,pH值7.4±0.2,加水溶解至1000ml、分装、灭 菌后备用。
实施例3的实验结果见表1。
表1抗厌氧菌活性(单位为ug/ml)
Figure BDA0001482917600000081
当抗厌氧菌活性值(单位为ug/ml)越低,抗菌所需的药物的量越少,该药 物则对抑制某种菌越有效。由表1可知,ustusol H2和TMC-120C对韦荣球菌的 抗菌效果更佳,ustusol H1对伊式放线菌的抗菌效果最佳;而ustusol H1,ustusolH2, ustusolH3、ustusolH4和TMC-120C均对双歧杆菌、乳酸杆菌、厌氧链球菌、普 通拟杆菌、消化链球菌有良好的抗菌效果。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何背离本发明的精神实质与原理下所作的改变、修饰、替代、组 合、简化、均应为等效的置换方式,都包含在本发明的保护范围内。
序列表
<110> 南京晓庄学院
<120> 产抗厌氧菌化合物的菌株和发酵方法、抗厌氧菌化合物提取及制备方法和使用方法
<130> xhx2017112401
<141> 2017-11-24
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 550
<212> DNA
<213> Aspergillus ustus
<400> 1
tacctgcgga aggatcatta ccgagtgcag gtctgccccc gggcaggcct aacctcccac 60
ccgtgaatac ctgaccaacg ttgcttcggc ggtgcgcccc cccgggggta gccgccggag 120
accacattga acctcttgtc tttagtgttg tctgagcttg atagcaaacc tattaaaact 180
ttcaacaatg gatctcttgg ttccggcatc gatgaagaac gcagcgaact gcgataagta 240
atgtgaattg cagaattcag tgaatcatcg agtctttgaa cgcacattgc gccccctggc 300
attccggggg gcatgcctgt ccgagcgtca ttgctgccct tcaagcccgg cttgtgtgtt 360
gggtcgtcgt cccccccggg ggacgggccc gaaaggcagc ggcggcaccg cgtccggtcc 420
tcgagcgtat ggggctttgt cacccgctcg attagggccg gccgggcgcc agccggcgtc 480
tccaaccttc tattttacca ggttgacctc ggatcaggta gggatacccg ctgaacttaa 540
gcatatcaaa 550

Claims (4)

1.一株产抗厌氧菌化合物的菌株,其为焦曲霉(Aspergillus ustus)A2,保藏编号为CCTCC NO.M 2017715。
2.权利要求1所述的产抗厌氧菌化合物的菌株在食品领域中的应用。
3.利用权利要求1所述的产抗厌氧菌化合物的菌株进行的发酵和产物富集方法,其特征是,所述方法包括以下步骤:
(a)将焦曲霉(Aspergillus ustus)A2在25℃,麦芽固体培养基活化培养7d后,取0.5cm2菌块接种到400mL麦芽液体培养基,在24℃恒温振荡箱中培养5d,得到该菌株液体种子液;
(b)将上述菌株液体种子液按8%接种量,接种到50g固体生产培养基,放置22℃恒温培养箱中培养25d,结束发酵,得到含有抗厌氧菌化合物的发酵产物;该菌株生产的抗厌氧菌化合物包括4个结构新型的补身烷类倍半萜化合物ustusol H1(焦曲霉素H1),ustusol H2(焦曲霉素H2),ustusol H3(焦曲霉素H3),ustusol H4(焦曲霉素H4)和已知化合物TMC-120C(2-(7-甲基-2,3-二氢呋喃[3,2-h]异喹啉-2-yl)丙醇-2-醇);
Figure FDA0003156906550000011
步骤(a)中,所述麦芽固体培养基的组成为:生麦芽20g、蛋白胨2g、羧甲基纤维素钠1g,K2HPO4 1g、KCl 0.5g、MgSO4 0.5g、FeSO4 0.01g、酵母膏1g,琼脂粉20g,加水溶解至1000ml、分装、灭菌后备用;不加琼脂,其余组成与上述的麦芽固体培养基相同,以形成所述的麦芽液体培养基;
步骤(b)中,所述固体生产培养基的制备步骤为:生麦芽20g、大米20g、麸皮10g,玉米芯10g,维生素C 0.5g,混合均匀后,加入72毫升水浸泡4h,灭菌后为固体生产培养基。
4.一类抗厌氧菌化合物提取及制备方法,其特征是,所述方法包括以下步骤:
(a)将权利要求3中发酵产物按照质量体积比为1:8的比例加入甲醇,25℃超声震荡30min,抽滤得到提取液;上述提取液中加入石油醚以体积比1:1进行萃取,取甲醇部分在40℃下抽真空旋转蒸发得到含抗厌氧菌化合物的浸膏;
(b)将上述浸膏通过流动相,流动相为甲醇:水且含0.1%HF,在反向色谱柱上进行梯度洗脱;收集甲醇:水体积比60-65%段,旋转蒸发仪蒸干,通过HPLC制备得到ustusol H1,ustusolH2,ustusolH3和ustusol H4;收集甲醇:水体积比70%段,旋转蒸发仪蒸干,通过HPLC制备得到TMC-120C;
所述ustusol H1,ustusolH2,ustusolH3和ustusol H4 HPLC制备条件是:色谱柱Allsphere ODS-2.5μm、250×4.6mm,柱温30℃,流动相甲醇:水体积比60%,出峰时间分别为16.2min,18.2min,21.05min和25.5min;
所述TMC-120C HPLC制备条件是:色谱柱Allsphere ODS-2.5μm、250×4.6mm,柱温30℃,流动相甲醇:水体积比65%,出峰时间为7.5min。
CN201711202062.0A 2017-11-27 2017-11-27 产抗厌氧菌化合物的菌株和发酵方法、抗厌氧菌化合物提取及制备方法和使用方法 Active CN108179114B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711202062.0A CN108179114B (zh) 2017-11-27 2017-11-27 产抗厌氧菌化合物的菌株和发酵方法、抗厌氧菌化合物提取及制备方法和使用方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711202062.0A CN108179114B (zh) 2017-11-27 2017-11-27 产抗厌氧菌化合物的菌株和发酵方法、抗厌氧菌化合物提取及制备方法和使用方法

Publications (2)

Publication Number Publication Date
CN108179114A CN108179114A (zh) 2018-06-19
CN108179114B true CN108179114B (zh) 2021-08-20

Family

ID=62545301

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711202062.0A Active CN108179114B (zh) 2017-11-27 2017-11-27 产抗厌氧菌化合物的菌株和发酵方法、抗厌氧菌化合物提取及制备方法和使用方法

Country Status (1)

Country Link
CN (1) CN108179114B (zh)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1721345A (zh) * 2001-01-23 2006-01-18 任啟刚 一种用复合微生物处理粪尿的方法
WO2006132669A3 (en) * 2004-11-15 2007-11-01 Bacterial Barcodes Inc Detection using primers to repetitive dna and transcription-based amplification thereby
CN101149377A (zh) * 2007-10-29 2008-03-26 南方医科大学珠江医院 用于检测曲霉的抗体
WO2009027470A1 (en) * 2007-08-30 2009-03-05 ÅGERUP, Bengt LOCAL ADMINISTRATION OF CHICKEN YOLK IMMUNE GLOBULINS (IgY) TO TREAT AND PREVENT FUNGAL INFECTIONS
WO2009059175A2 (en) * 2007-11-01 2009-05-07 Novozymes, Inc. Methods of reducing the inhibitory effect of a tannin of the enzymatic hydrolysis of cellulosic material
CN101838618A (zh) * 2009-07-02 2010-09-22 江苏奕农生物工程有限公司 一种高α-半乳糖苷类寡糖降解能力的中性α-半乳糖苷酶Aga-S27及其基因和应用
EP3089967A1 (en) * 2013-10-23 2016-11-09 The United States of America, as represented by The Secretary, Department of Health and Human Services Small molecule imaging of fungi by positron emission tomography scanning
CN106755040A (zh) * 2016-12-26 2017-05-31 南京晓庄学院 产适冷α‑淀粉酶菌株、构建方法和生产α‑淀粉酶的方法
CN106820134A (zh) * 2017-02-21 2017-06-13 南京晓庄学院 一种基于芝芪菌质的免疫增强剂的制备方法和用途
CN106923133A (zh) * 2017-05-12 2017-07-07 南京晓庄学院 一种控制蘑菇采后褐变的方法
BR102015021015A2 (pt) * 2015-08-31 2018-04-03 Universidade Federal Do Paraná Processo para produção de lipídeos à partir de derivados do sorgo sacarino

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3131574B2 (ja) * 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
CA2558870A1 (en) * 2004-04-06 2005-10-20 Metanomics Gmbh Process for the production of fine chemicals
WO2008085549A2 (en) * 2006-07-28 2008-07-17 Board Of Regents Of The University Of Texas System Compositions and methods for stimulation of lung innate immunity
JP5268461B2 (ja) * 2008-07-14 2013-08-21 Meiji Seikaファルマ株式会社 Pf1364物質、その製造方法、生産菌株、及び、それを有効成分とする農園芸用殺虫剤
EP2317857B1 (en) * 2008-07-29 2016-12-28 Frontier Scientific, Inc. Use of tetrakis(n-alkylpyridinium)-porphyrin derivatives for killing microbes or preventing their growth
WO2010118463A1 (en) * 2009-04-17 2010-10-21 Biocentral Laboratories Ltd. Biocontrol fungi
US8450059B2 (en) * 2009-04-27 2013-05-28 Fred Hutchinson Cancer Research Center Quantitative PCR-based compositions and methods for the diagnosis of invasive pulmonary aspergillosis
ES2699747T3 (es) * 2011-04-29 2019-02-12 Danisco Us Inc Microorganismos recombinantes para la producción potenciada de mevalonato, isopreno e isoprenoides
DK2764084T4 (da) * 2011-10-07 2021-12-06 Danisco Us Inc Anvendelse af phosphoketolase i fremstillingen af mevalonat, isoprenoid-udgangsstoffer, og isopren
CN102659912B (zh) * 2012-03-27 2014-03-12 中国科学院烟台海岸带研究所 一种多氧二倍半萜类化合物及其制备和应用
CN103232945B (zh) * 2013-05-20 2014-08-13 武汉大学 一种高产蛇孢假壳素类化合物菌株焦曲霉tkyx429及其应用
CN104762216B (zh) * 2014-12-26 2017-11-10 南京晓庄学院 一种抗盐胁迫真菌菌株及选育方法和其应用
CN104673813B (zh) * 2015-03-24 2017-07-28 武汉大学 一种蛇孢假壳素类化合物母核合成基因AuOS及其应用
CN105647879A (zh) * 2016-03-16 2016-06-08 武汉大学 一种二萜化合物variediene合成基因Au13192及其应用
CN106518643B (zh) * 2016-10-14 2019-02-15 宁波大学 一种环戊烯酮类化合物及其制备方法和用途

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1721345A (zh) * 2001-01-23 2006-01-18 任啟刚 一种用复合微生物处理粪尿的方法
WO2006132669A3 (en) * 2004-11-15 2007-11-01 Bacterial Barcodes Inc Detection using primers to repetitive dna and transcription-based amplification thereby
WO2009027470A1 (en) * 2007-08-30 2009-03-05 ÅGERUP, Bengt LOCAL ADMINISTRATION OF CHICKEN YOLK IMMUNE GLOBULINS (IgY) TO TREAT AND PREVENT FUNGAL INFECTIONS
CN101149377A (zh) * 2007-10-29 2008-03-26 南方医科大学珠江医院 用于检测曲霉的抗体
WO2009059175A2 (en) * 2007-11-01 2009-05-07 Novozymes, Inc. Methods of reducing the inhibitory effect of a tannin of the enzymatic hydrolysis of cellulosic material
CN101838618A (zh) * 2009-07-02 2010-09-22 江苏奕农生物工程有限公司 一种高α-半乳糖苷类寡糖降解能力的中性α-半乳糖苷酶Aga-S27及其基因和应用
EP3089967A1 (en) * 2013-10-23 2016-11-09 The United States of America, as represented by The Secretary, Department of Health and Human Services Small molecule imaging of fungi by positron emission tomography scanning
BR102015021015A2 (pt) * 2015-08-31 2018-04-03 Universidade Federal Do Paraná Processo para produção de lipídeos à partir de derivados do sorgo sacarino
CN106755040A (zh) * 2016-12-26 2017-05-31 南京晓庄学院 产适冷α‑淀粉酶菌株、构建方法和生产α‑淀粉酶的方法
CN106820134A (zh) * 2017-02-21 2017-06-13 南京晓庄学院 一种基于芝芪菌质的免疫增强剂的制备方法和用途
CN106923133A (zh) * 2017-05-12 2017-07-07 南京晓庄学院 一种控制蘑菇采后褐变的方法

Also Published As

Publication number Publication date
CN108179114A (zh) 2018-06-19

Similar Documents

Publication Publication Date Title
CN107298671B (zh) 源于草酸青霉的黑麦酮酸h及制备抗人结肠癌药物的应用
CN109423465B (zh) 一种控制黄曲霉毒素b1的复合生物制剂及其应用
CN107353274B (zh) 源于草酸青霉的黑麦酮酸i及制备抗人食管癌药物的应用
CN107298672B (zh) 源于草酸青霉的黑麦酮酸i在制备抗人结肠癌药物的应用
CN113980848B (zh) 一种戊糖片球菌sbc5及其应用
CN113604402A (zh) 一种特异性的乳酸菌培养基及其培养方法和应用
CN115806881B (zh) 一种青霉属真菌及其在制备抗菌药物中的应用
CN107485607B (zh) 源于草酸青霉的黑麦酮酸h在制备抗人食管癌药物的应用
CN107298670B (zh) 源于草酸青霉黑麦酮酸h制备抗人口腔表皮样癌药物应用
JP5916132B2 (ja) エクオールの製造方法
CN113293110B (zh) 一种抗菌脂肽类化合物的制备方法
CN112760233B (zh) 一株深海来源的棘孢曲霉菌、其代谢产物及应用
CN107298669B (zh) 源于草酸青霉的黑麦酮酸i及抗人口腔表皮样癌药物应用
CN108179114B (zh) 产抗厌氧菌化合物的菌株和发酵方法、抗厌氧菌化合物提取及制备方法和使用方法
CN110003153B (zh) 一种苯并呋喃类化合物及其制备方法和用途
CN115725420A (zh) 一株产黄酮类化合物的工业大麻内生真菌及其应用
CN107686817B (zh) 一株阔苞菊内生真菌CYSK-4及其生产的Ascomylactam类化合物的应用
CN113234050B (zh) 一种抗菌化合物、制备方法及其应用
CN114410479A (zh) 一株甘蔗内生真菌及其在生产多酚和抑菌方面的应用
CN111944019B (zh) 一种抗菌多肽类化合物及其制备方法和用途
CN113322192A (zh) 一种黄精内生真菌抑制大肠杆菌剂及其制备方法和应用
CN108660169B (zh) 一种发酵制备棘孢菌素类抗生素的方法
CN108794502B (zh) 一种单端孢霉烯类化合物及其制备方法和用途
CN113337403A (zh) 一种球毛壳菌hjf 13菌株及其应用
CN109971655B (zh) 一株黄芪内生球毛壳菌(Chaetomium sp.)HQ-1及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant